Erin Pettijohn, MD
Hematology & Oncology · Grand Rapids, MINPI 1003101429
Payments from drug & device makers
Across 688 payments — averaging $1265.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$338K
- Seagen Inc.$322K
- Bristol Myers Squibb$100K
- AbbVie$47K
- Regeneron$32K
- Takeda Pharmaceuticals U.S.A., Inc.$16K
- plus $16K from 54 others
What the payments were for
- Food & beverage$10,025100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIBSOVO$153
- IDHIFA$153
- FOUNDATIONONE$112
- FOUNDATIONONE HEME$112
- FOUNDATIONONE CDX$112
- FOUNDATIONFOCUS$112
- FOUNDATIONONE LIQUID$112
How this compares
$870,954 in reported general payments places this provider in the 90th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 274 | $4,586,440 |
| ImbruvicaIbrutinib | 183 | $2,799,777 |
| Lenalidomide | 161 | $2,236,167 |
| PomalystPomalidomide | 93 | $2,076,784 |
| VenclextaVenetoclax | 114 | $1,235,821 |
| JakafiRuxolitinib Phosphate | 68 | $1,207,213 |
| PromactaEltrombopag Olamine | 38 | $495,418 |
| SprycelDasatinib | 31 | $443,485 |
| TasignaNilotinib Hcl | 28 | $419,062 |
| CalquenceAcalabrutinib Maleate | 30 | $377,027 |
| Bexarotene | 12 | $318,615 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $307,480 |
| BosulifBosutinib | 12 | $236,948 |
| InqoviDecitabine/Cedazuridine | 20 | $161,411 |
| NeulastaPegfilgrastim | 25 | $157,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $99,967 | $4,586,440274 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $272 | $2,799,777183 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $171 | $2,520,270124 claims |
| AbbVieVenclexta | $47,287 | $1,235,821114 claims |
| Incyte CorporationJakafi | $396 | $1,207,21368 claims |
| NovartisPromacta, Tasigna | $731 | $914,48066 claims |
| PfizerBosulif, Nyvepria, Eliquis | $408 | $441,340134 claims |
| AstraZenecaCalquence | $678 | $377,02730 claims |
| GSKOjjaara | $424 | $307,48012 claims |
| Taiho Oncology, Inc.Inqovi | $60 | $161,41120 claims |
| AmgenNeulasta | $161 | $157,78725 claims |
| Beigene USA, Inc.Brukinsa | $55 | $151,20615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Grand Rapids
- Sreenivasa ChandanaGrand Rapids$19.1M
- Nehal LakhaniGrand Rapids$15M
- Brett BrinkerGrand Rapids$2.3M
- Eric SantosGrand Rapids$1.5M
- Andrew SochackiGrand Rapids$1.4M
- Amy Vander WoudeGrand Rapids$1.2M
- Colin HardinGrand Rapids$974K
- Latha PolavaramGrand Rapids$69K
- Timothy OrourkeGrand Rapids$55K
- Hirva MamdaniDetroit$9.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.